Lisa Sideris: The Power of Plasma Donation in Alpha 1 Care
Lisa Sideris, Alpha-1 Patient Advocate and Rare Disease Speaker at Alpha-1 Foundation, shared a post on LinkedIn:
“900.
That’s the exact number of plasma donations it takes each year to provide the therapy needed to keep just one Alpha 1 patient alive and breathing.
I shared that statistic on Capitol Hill this week with the Congressional Plasma Caucus, alongside the Plasma Protein Therapeutics Association (PPTA) .
The room went silent.
Before I was diagnosed with Alpha 1 Antitrypsin Deficiency, a rare genetic disease that affects the lungs and liver, my reality looked like this:
- 3 years searching for answers
- 7 to 10 different specialists
- A portion of my left lung removed completely unnecessarily
Today, plasma derived therapies remain essential and while we work toward new treatments, we must make sure patients who rely on plasma today continue to have access to the therapies they need.
No donors mean no treatment. Its really that simple.
To everyone who has ever sat in a chair to donate plasma: thank you.
You aren’t just a donor.
You’re someone’s 900.”
David McIntosh, Founder and Chair of United Plasma Action, shared Lisa Sideris’s post on LinkedIn:
“This post is a striking reminder of how important Alpha 1 Antitripsin is for the patients who need it.
Made from precious human plasma donations, Alpha 1 has no effective alternatives or substitutes and yet is NOT always given the policy priority that it deserves.
Attention please, all Health Authorities and Regulators.”

Stay updated with Hemostasis Today.
-
Nov 20, 2026, 17:27Adam Bryant: Great Science, Valuable Connections and a Wonderful Haematology Community at Blood 2026
-
Nov 20, 2026, 17:25Gurpreet Kaurr: Scientific Discussions, New Perspectives and Inspiration at HAEMATOCON 2026
-
Nov 20, 2026, 17:24Bispecific FVIIIa-Mimetic Antibodies in Haemophilia A – CRH French Reference Center for Hemophilia Lyon
-
Nov 20, 2026, 17:23Khalid Rehman: Psychosocial Burden Among Caregivers of Patients with Beta-Thalassemia Major in Pakistan
-
Nov 20, 2026, 17:20Dhinesh Selvaraju: Caplacizumab Becomes the First FDA-Approved Treatment for Pediatric aTTP
-
Nov 20, 2026, 17:19Paris Margaritis: Presenting Preclinical Data on GENV-HEM at the WFH Workshop
-
Nov 20, 2026, 17:18WFH Opens Public Comment on Draft Guidelines for Hemostatic Agents and Prophylaxis
-
Nov 20, 2026, 17:18Ketan Asawale: Consensus on the Management of Cancer-Associated Thrombosis in India
-
Nov 20, 2026, 17:16Ajay Samkaria: The Evolution of Hemostasis Diagnostics with the ACL TOP 70 Series